U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07681414) titled 'ctDNA Assessment in Endometrial Cancer for Adjuvant Therapy' on June 27.
Brief Summary: The goal of this observational study is to evaluate whether combining postoperative circulating tumor DNA (ctDNA) testing with a novel genomic risk model can better predict recurrence risk and guide adjuvant therapy decisions in patients with endometrial cancer.
The main questions it aims to answer are:
* Can the Clinico-Genomic Risk Score (CGRS) model, which integrates POLE hypermutation, TP53 mutation, FIGO grade, and hormone receptor status, effectively stratify patients into different prognosis groups?
* Is postoperative ctDNA positivity as...